Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update
AnaptysBio (NASDAQ:ANAB) reported Q2 2025 financial results and significant clinical progress. The company announced positive Phase 2b data for rosnilimab in rheumatoid arthritis, showing JAK-like efficacy and durable responses. Enrollment was completed for the Phase 2 ulcerative colitis trial, with top-line data expected in Q4 2025.
Financial highlights include $293.7M in cash as of June 30, 2025, collaboration revenue of $22.3M for Q2, and a net loss of $38.6M. The company expects to trigger a $75M milestone payment from GSK when Jemperli reaches $1B in annual sales. AnaptysBio has repurchased 2.85M shares (9.3%) under its stock buyback program and maintains cash runway through 2027.
The company plans to initiate a Phase 1b trial for ANB033 in celiac disease by Q4 2025 and continues Phase 1 trials for ANB033 and ANB101 in healthy volunteers.
AnaptysBio (NASDAQ:ANAB) ha riportato i risultati finanziari del secondo trimestre 2025 e importanti progressi clinici. L'azienda ha annunciato dati positivi di Fase 2b per rosnilimab nell'artrite reumatoide, mostrando un'efficacia simile a JAK e risposte durature. 脠 stato completato il reclutamento per lo studio di Fase 2 sulla colite ulcerosa, con dati preliminari attesi nel quarto trimestre 2025.
I punti salienti finanziari includono 293,7 milioni di dollari in liquidit脿 al 30 giugno 2025, ricavi da collaborazioni per 22,3 milioni di dollari nel secondo trimestre e una perdita netta di 38,6 milioni di dollari. L'azienda prevede di attivare un pagamento milestone di 75 milioni di dollari da GSK quando Jemperli raggiunger脿 1 miliardo di dollari di vendite annuali. AnaptysBio ha riacquistato 2,85 milioni di azioni (9,3%) nell鈥檃mbito del suo programma di buyback e mantiene una liquidit脿 sufficiente fino al 2027.
L'azienda prevede di avviare uno studio di Fase 1b per ANB033 nella celiachia entro il quarto trimestre 2025 e continua gli studi di Fase 1 per ANB033 e ANB101 su volontari sani.
AnaptysBio (NASDAQ:ANAB) inform贸 los resultados financieros del segundo trimestre de 2025 y avances cl铆nicos significativos. La compa帽铆a anunci贸 datos positivos de la Fase 2b para rosnilimab en artritis reumatoide, mostrando una eficacia similar a JAK y respuestas duraderas. Se complet贸 la inscripci贸n para el ensayo de Fase 2 en colitis ulcerosa, con datos preliminares esperados en el cuarto trimestre de 2025.
Los aspectos financieros destacados incluyen
La compa帽铆a planea iniciar un ensayo de Fase 1b para ANB033 en enfermedad cel铆aca para el cuarto trimestre de 2025 y contin煤a con los ensayos de Fase 1 para ANB033 y ANB101 en voluntarios sanos.
AnaptysBio (NASDAQ:ANAB)電� 2025雲� 2攵勱赴 鞛 鞁れ爜瓿� 欷戩殧頃� 鞛勳儊 歆勳爠鞚� 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 毳橂韹办姢 甏�鞝堨椉鞐� 雽�頃� rosnilimab鞚� 2b靸� 旮嶌爼鞝� 雿办澊韯�毳� 瓿店皽頄堨溂氅�, JAK 鞙犾偓 須姤瓿� 歆�靻嶌爜鞚� 氚橃潙鞚� 氤挫棳欤检棃鞀惦媹雼�. 甓れ枒靹� 雽�鞛レ椉 2靸� 鞁滍棙鞚� 霌彪鞚� 鞕勲霅橃棃鞙茧┌, 2025雲� 4攵勱赴鞐� 欤检殧 瓴瓣臣臧� 氚滍憸霅� 鞓堨爼鞛呺媹雼�.
鞛 頃橃澊霛检澊韸鸽電� 2025雲� 6鞗� 30鞚� 旮办 2鞏� 9,370毵� 雼煬 順勱笀 氤挫湢, 2攵勱赴 順戨牓 靾橃澋 2,230毵� 雼煬, 靾滌啇鞁� 3,860毵� 雼煬臧� 韽暔霅╇媹雼�. 須岇偓電� Jemperli臧� 鞐瓣皠 毵れ稖 10鞏� 雼煬毳� 雼劚頃橂┐ GSK搿滊秬韯� 7,500毵� 雼煬 毵堨澕鞀ろ啢 歆�旮�鞚� 氚涭潉 瓴冹溂搿� 鞓堨儊頃╇媹雼�. AnaptysBio電� 鞛愳偓欤� 毵れ瀰 頂勲攴鸽灗鞚� 韱淀暣 285毵� 欤�(9.3%)毳� 鞛Г鞛呿枅鞙茧┌ 2027雲勱箤歆� 順勱笀 鞙犽彊靹膘潉 鞙犾頃橁碃 鞛堨姷雼堧嫟.
須岇偓電� 2025雲� 4攵勱赴旯岇 靺�毽晠氤戩棎 雽�頃� ANB033 1b靸� 鞁滍棙鞚� 鞁滌瀾頃� 瓿勴殟鞚措┌, 瓯搓皶頃� 歆�鞗愳瀽毳� 雽�靸侅溂搿� ANB033 氚� ANB101 1靸� 鞁滍棙鞚� 瓿勳啀 歆勴枆 欷戩瀰雼堧嫟.
AnaptysBio (NASDAQ:ANAB) a publi茅 ses r茅sultats financiers du deuxi猫me trimestre 2025 ainsi que des progr猫s cliniques significatifs. La soci茅t茅 a annonc茅 des donn茅es positives de Phase 2b pour rosnilimab dans la polyarthrite rhumato茂de, montrant une efficacit茅 comparable 脿 celle des inhibiteurs JAK et des r茅ponses durables. Le recrutement pour l'essai de Phase 2 sur la colite ulc茅reuse est termin茅, avec des donn茅es principales attendues au quatri猫me trimestre 2025.
Les points financiers cl茅s incluent 293,7 millions de dollars en liquidit茅s au 30 juin 2025, un chiffre d'affaires de collaboration de 22,3 millions de dollars au deuxi猫me trimestre et une perte nette de 38,6 millions de dollars. La soci茅t茅 s'attend 脿 d茅clencher un paiement d'茅tape de 75 millions de dollars de GSK lorsque Jemperli atteindra un milliard de dollars de ventes annuelles. AnaptysBio a rachet茅 2,85 millions d'actions (9,3 %) dans le cadre de son programme de rachat d'actions et dispose de liquidit茅s suffisantes jusqu'en 2027.
La soci茅t茅 pr茅voit de lancer un essai de Phase 1b pour ANB033 dans la maladie c艙liaque d'ici le quatri猫me trimestre 2025 et poursuit les essais de Phase 1 pour ANB033 et ANB101 chez des volontaires sains.
AnaptysBio (NASDAQ:ANAB) berichtete die Finanzergebnisse f眉r das zweite Quartal 2025 sowie bedeutende klinische Fortschritte. Das Unternehmen gab positive Phase-2b-Daten f眉r rosnilimab bei rheumatoider Arthritis bekannt, die eine JAK-盲hnliche Wirksamkeit und anhaltende Reaktionen zeigten. Die Einschreibung f眉r die Phase-2-Studie zur Colitis ulcerosa wurde abgeschlossen, die Topline-Daten werden im vierten Quartal 2025 erwartet.
Finanzielle Highlights umfassen 293,7 Mio. USD an liquiden Mitteln zum 30. Juni 2025, Kollaborationsums盲tze von 22,3 Mio. USD im zweiten Quartal und einen Nettoverlust von 38,6 Mio. USD. Das Unternehmen erwartet eine Meilensteinzahlung von 75 Mio. USD von GSK, wenn Jemperli einen Jahresumsatz von 1 Mrd. USD erreicht. AnaptysBio hat im Rahmen seines Aktienr眉ckkaufprogramms 2,85 Mio. Aktien (9,3 %) zur眉ckgekauft und verf眉gt 眉ber ausreichende Liquidit盲t bis 2027.
Das Unternehmen plant, bis zum vierten Quartal 2025 eine Phase-1b-Studie f眉r ANB033 bei Z枚liakie zu starten und f眉hrt weiterhin Phase-1-Studien f眉r ANB033 und ANB101 an gesunden Freiwilligen durch.
- Positive Phase 2b rosnilimab data showing JAK-like efficacy and durable responses in rheumatoid arthritis
- Expected $75M milestone payment from GSK in 2025 for Jemperli sales
- Strong cash position of $293.7M with runway through 2027
- Collaboration revenue increased to $22.3M in Q2 2025 from $11.0M in Q2 2024
- 9.3% of shares repurchased under buyback program
- Net loss per share improved to $1.34 in Q2 2025 from $1.71 in Q2 2024
- Net loss of $38.6M in Q2 2025
- Cash decreased by $127.1M from December 2024
- Increased G&A expenses to $10.6M from $9.3M year-over-year
Insights
Anaptys reports positive Phase 2b rosnilimab data with JAK-like efficacy in RA and durable off-drug effects, while advancing multiple clinical programs.
Anaptys has delivered an impressive quarter with significant clinical achievements across its immunology pipeline. The standout news is rosnilimab's positive Phase 2b data in rheumatoid arthritis, demonstrating what the company describes as "JAK-like efficacy" with monthly dosing and a favorable safety profile compared to existing treatments. Notably, patients maintained durable responses for 12-14 weeks after stopping treatment, suggesting potential for extended dosing intervals that could provide a competitive advantage in this crowded market.
The company has also completed enrollment in rosnilimab's Phase 2 ulcerative colitis trial (136 patients), with top-line data expected in Q4 2025. This study includes a treatment extension allowing for up to 50 weeks of therapy, which will provide valuable long-term efficacy and safety data.
Beyond rosnilimab, Anaptys is advancing two early-stage candidates: ANB033 (CD122 antagonist) and ANB101 (BDCA2 modulator). The company has selected celiac disease as ANB033's initial indication - a strategic choice targeting an autoimmune condition affecting 2.1 million Americans with no approved therapies. ANB033's mechanism of inhibiting both IL-2 and IL-15 signaling appears well-suited for celiac disease's pathology.
On the financial front, Anaptys maintains a strong cash position of
While the quarterly net loss of
Rosnilimab shows impressive durability with JAK-like efficacy but better safety in RA, with potential as first-in-class pathogenic T cell depleter.
The rosnilimab Phase 2b rheumatoid arthritis data represents a potential breakthrough in autoimmune disease treatment. As a pathogenic T cell depleter, rosnilimab targets disease-driving T cells while sparing regulatory T cells, a mechanism fundamentally different from JAK inhibitors, TNF blockers, or IL-6 antagonists. The trial data reveals three particularly noteworthy aspects:
First, the durability of response after drug discontinuation is exceptional. Patients who achieved Clinical Disease Activity Index Low Disease Activity (CDAI LDA) at Week 28 maintained responses for 12-14 weeks off treatment. This suggests rosnilimab may be modifying the underlying immunopathology rather than just suppressing symptoms, potentially allowing for extended dosing intervals (Q8W or Q12W).
Second, the safety profile appears superior to JAK inhibitors while delivering comparable efficacy. JAK inhibitors, while effective, carry black box warnings for serious adverse events including infections, cardiovascular events, and malignancies. If rosnilimab maintains this safety advantage in larger studies, it could significantly disrupt the treatment paradigm for RA.
Third, the observation that "max response rates have not yet been observed" suggests potential for even greater efficacy with continued treatment. This is particularly intriguing since the trial's strict continuation criteria at three months excluded patients who were trending toward but hadn't yet achieved Low Disease Activity and ACR50 responses.
For the ulcerative colitis program, the trial design is particularly robust with 50% of enrolled patients having experience with advanced therapies. This enriched population will provide valuable insights into rosnilimab's efficacy in treatment-resistant patients. The inclusion of a treatment extension period up to 50 weeks will generate critical long-term data in a disease where maintaining remission is as challenging as inducing it.
The selection of celiac disease for ANB033 is scientifically sound, as both IL-2 and IL-15 drive the pathogenic intraepithelial lymphocytes that damage intestinal epithelium in response to gluten. With no FDA-approved therapies for celiac disease, ANB033 could address a significant unmet need if successful.
- Announces positive data for rosnilimab, a pathogenic T cell depleter, through Week 38 from Phase 2b rheumatoid arthritis trial
- Enrollment completed for rosnilimab Phase 2 ulcerative colitis trial; Top-line data through Week 12 on track for Q4 2025
- Ongoing Phase 1 trials in healthy volunteers for ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulator
- Plan to initiate Phase 1b cohort for ANB033 in initial indication, celiac disease, by Q4 2025; additional information to be disclosed at ANB033-focused R&D event in Q4 2025
- Anticipate triggering a
$75 million commercial sales milestone from GSK in 2025 once Jemperli achieves$1 billion in worldwide net sales in a calendar year
SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.
鈥淩osnilimab鈥檚 Phase 2b data in rheumatoid arthritis (RA) delivered a compelling safety and tolerability profile and JAK-like efficacy through six months that is durable for at least three months off-drug. The strength of the data, as well as positive feedback from the KOL community, gives us confidence in the transformational potential of rosnilimab. With enrollment completed in the Phase 2 ulcerative colitis (UC) trial, we look forward to reading out top-line data through Week 12 in Q4 2025, as well as potential additional six- and 12-month data from this trial in 2026,鈥� said Daniel Faga, president and chief executive officer of Anaptys. 鈥淎dditionally, we are excited to announce the initial indication for our CD122 antagonist, ANB033, is celiac disease (CeD), a serious autoimmune disease triggered by the ingestion of gluten, affecting more than 2.1 million people in the U.S. but with no approved therapies. We believe ANB033鈥檚 MoA, inhibiting both IL-2 and IL-15 signaling, is well-suited to target the multiple pathogenic drivers of CeD. We plan to initiate a Phase 1b cohort by Q4 2025 and will discuss the program in depth at a dedicated R&D event later this year.鈥�
PORTFOLIO UPDATES
Rosnilimab (Pathogenic T Cell Depleter)
- Announced positive data for rosnilimab from robust, 424-patient Phase 2b RA trial demonstrating 鈥�
- Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month鈥� blinded treatment period
- Favorable safety and tolerability, particularly when compared to standard of care biologics or JAK inhibitors
- Max response rates have not yet been observed; strict continuation criteria at three months in this Phase 2b trial excluded many patients who either achieved or were trending toward LDA and ACR50
- Trial now complete with CDAI LDA responders at Week 28 demonstrating durable responses for at least 12-14 weeks off drug through Week 38
- Data consistent with previously reported partial data results through Week 34
- Supports potential for maintenance dosing with extended dosing intervals (e.g. Q8W or Q12W)
- Safety profile remains favorable and consistent with previously reported data
- Plan to present complete RA Phase 2b data at a future medical congress
- Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month鈥� blinded treatment period
- Enrollment complete for global Phase 2 trial in moderate-to-severe UC (N=136, ~
50% advanced therapy experienced)- Assessing Q2W and Q4W dose levels of subcutaneously administered rosnilimab vs. placebo (randomized 1:1:1)
- Primary statistical analysis at Week 12 on well-established endpoints, including the primary endpoint of change from baseline in modified Mayo score (mMS) and key secondary endpoints, such as clinical response and remission on mMS
- All patients in all three study arms treat-through to Week 24 and remain blinded to treatment arm. Placebo-treated patients who achieved clinical response on partial modified Mayo score (pmMS) at Week 12 remain on placebo, while placebo-treated patients who are non-responders are crossed over to the high dose Q2W rosnilimab treatment arm
- Patients who are in clinical response on pmMS at Week 24 are eligible for an additional 26-week (50 weeks of total treatment) blinded treatment extension period (TEP)
- Top-line data through Week 12, including primary and key secondary endpoints, on track for Q4 2025
- Blinded surveillance data to date suggest a favorable safety and tolerability profile consistent with prior rosnilimab trials
- Blinded surveillance data to date suggest a favorable safety and tolerability profile consistent with prior rosnilimab trials
- Assessing Q2W and Q4W dose levels of subcutaneously administered rosnilimab vs. placebo (randomized 1:1:1)
ANB033 (CD122 antagonist)
- Phase 1 trial ongoing in healthy volunteers
- Plan to initiate Phase 1b cohort for ANB033 in initial indication, celiac disease, by Q4 2025
- Additional information to be disclosed at ANB033-focused R&D event in Q4 2025
ANB101 (BDCA2 modulator)
- Phase 1 trial ongoing in healthy volunteers
COLLABORATION UPDATES
GSK Immuno-Oncology Financial Collaboration
- GSK announced strong commercial performance for Jemperli (
$262 million /拢196 million in Q2 2025 sales;$482 million /拢370 million in 1H 2025 sales) with >19% USD and >12% GBP quarter-over-quarter growth- Anaptys anticipates triggering a one-time
$75 million commercial sales milestone from GSK in 2025 once Jemperli achieves$1 billion in worldwide net sales in a calendar year
- Anaptys anticipates triggering a one-time
- Substantial GSK investment in additional indications of Jemperli monotherapy and combinations ongoing -
- AZUR-1 pivotal Phase 2 trial of dostarlimab monotherapy in patients with untreated stage II/III dMMR/MSI-H locally advanced rectal cancer
- Top-line data in H2 2026
- Jemperli received U.S. FDA Breakthrough Therapy Designation for this indication
- AZUR-2 pivotal Phase 3 trial of perioperative dostarlimab monotherapy versus standard of care in participants with untreated T4N0 or stage III dMMR/ MSI-H resectable colon cancer ongoing
- AZUR-4 Phase 2 trial of neoadjuvant dostarlimab plus capecitabine plus oxaliplatin (CAPEOX) versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon cancer ongoing
- JADE pivotal Phase 3 trial of dostarlimab versus placebo as sequential therapy after chemoradiation in participants with locally advanced unresected head and neck squamous cell carcinoma (HNSCC) ongoing
- GSK announced that COSTAR Lung Phase 3 trial did not meet primary endpoint of overall survival
- AZUR-1 pivotal Phase 2 trial of dostarlimab monotherapy in patients with untreated stage II/III dMMR/MSI-H locally advanced rectal cancer
Vanda Imsidolimab Financial Collaboration
- Vanda anticipates FDA BLA submission for generalized pustular psoriasis (GPP) in 2H 2025
- Anaptys eligible to receive up to
$35 million for future regulatory approval, including a$5 million milestone upon U.S. FDA approval, and sales milestones, in addition to a10% royalty on net sales
- Anaptys eligible to receive up to
FINANCIAL UPDATES
Stock Repurchase Program and Cash Runway
- The Company has repurchased a total of 2,853,836 shares of common stock (
9.3% shares outstanding) with$55.5 million as of June 30, 2025 from its$75.0 million Stock Repurchase Program - Cash and investments of听
$293.7 million 听as of June 30, 2025, and reiterating cash runway through year-end 2027
Second Quarter 2025 Financial Results
- Cash, cash equivalents and investments totaled
$293.7 million as of June 30, 2025, compared to$420.8 million as of December听31, 2024, for a decrease of$127.1 million due primarily to operating activities and$55.5 million in shares repurchased, offset by$15.0 million received from Vanda Pharmaceuticals for the license of imsidolimab. - Collaboration revenue was
$22.3 million and$50.0 million for the three and six months ended June 30, 2025, compared to$11.0 million and$18.2 million for the three and six months ended June 30, 2024. This was due primarily to Jemperli royalties increasing$11.0 million and$22.1 million for the three and six months ended June 30, 2025 and$9.7 million in revenue recognized for the Vanda license agreement. - Research and development expenses were
$37.8 million and$79.0 million for the three and six months ended June 30, 2025, compared to$42.0 million and$79.0 million for the three and six months ended June 30, 2024. The decrease for the three months ended June 30, 2025, was primarily due to lower development costs for ANB032 and imsidolimab offset by higher costs relating to the Phase 2 trials in RA and UC for rosnilimab and the Phase 1 trials for ANB033 and ANB101. The R&D non-cash, stock-based compensation expense was$4.5 million and$8.9 million for the three and six months ended June 30, 2025 as compared to$3.5 million and$7.0 million in the same period in 2024. - General and administrative expenses were
$10.6 million and$24.7 million for the three and six months ended June 30, 2025, compared to$9.3 million and$21.6 million for the three and six months ended June 30, 2024. The increase was due primarily to transaction costs associated with the Vanda Pharmaceuticals license agreement. The G&A non-cash, stock-based compensation expense was$4.8 million and$9.5 million for the three and six months ended June 30, 2025 as compared to$4.0 million and$10.7 million in the same period in 2024. - Net loss was
$38.6 million and$78.0 million for the three and six months ended June 30, 2025, or a net loss per share of$1.34 and$2.62 , compared to a net loss of$46.7 million and$90.6 million for the three and six months ended June 30, 2024, or a net loss per share of$1.71 and$3.35 .
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a pathogenic T cell depleter, completed a Phase 2b trial for the treatment of rheumatoid arthritis and is in a Phase 2 trial for the treatment of ulcerative colitis. The company鈥檚 pipeline also includes ANB033, a CD122 antagonist, being studied in celiac disease and ANB101, a BDCA2 modulator, both in Phase 1 trials. Anaptys has also discovered and out-licensed in financial collaborations multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli听(dostarlimab-gxly)) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals. To learn more, visit听听or follow us on听.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: the timing of the release of data from the Company鈥檚 clinical trials, including rosnilimab鈥檚 top-line Phase 2 clinical trial data in ulcerative colitis; whether positive clinical trial results in rosnilimab鈥檚 Phase 2b clinical trial in rheumatoid arthritis increases the likelihood of getting positive results from rosnilimab鈥檚 Phase 2 clinical trial in ulcerative colitis; timing of the R&D event for ANB033; timing of the initiation of the ANB033 phase 1b cohort in celiac disease; the potential to receive any royalties or milestone payments from the Vanda Pharmaceuticals license agreement; the potential to receive any additional milestones and royalties from the GSK collaboration and the timing therefor; and the Company's projected cash runway. Statements including words such as 鈥減lan,鈥� 鈥渃ontinue,鈥� 鈥渆xpect,鈥� or 鈥渙ngoing鈥� and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements are subject to risks and uncertainties that may cause the company鈥檚 actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the company鈥檚 ability to advance its product candidates, obtain regulatory approval of and ultimately commercialize its product candidates, the timing and results of preclinical and clinical trials, the company鈥檚 ability to fund development activities and achieve development goals, the company鈥檚 ability to protect intellectual property and other risks and uncertainties described under the heading 鈥淩isk Factors鈥� in documents the company files from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
| 听 | |||||||
| AnaptysBio, Inc. Consolidated Balance Sheets (in thousands, except par value data) (unaudited) | |||||||
| 听 | |||||||
| 听 | June 30, 2025 | 听 | December 31, 2024 | ||||
| 听 | 听 | 听 | 听 | ||||
| ASSETS | |||||||
| Current assets: | 听 | 听 | 听 | ||||
| Cash and cash equivalents | $ | 44,298 | 听 | 听 | $ | 123,080 | 听 |
| Receivables from collaborative partners | 听 | 21,418 | 听 | 听 | 听 | 40,765 | 听 |
| Short-term investments | 听 | 221,412 | 听 | 听 | 听 | 262,293 | 听 |
| Prepaid expenses and other current assets | 听 | 4,778 | 听 | 听 | 听 | 5,738 | 听 |
| Total current assets | 听 | 291,906 | 听 | 听 | 听 | 431,876 | 听 |
| Property and equipment, net | 听 | 1,628 | 听 | 听 | 听 | 1,849 | 听 |
| Operating lease right-of-use assets | 听 | 13,464 | 听 | 听 | 听 | 14,383 | 听 |
| Long-term investments | 听 | 27,996 | 听 | 听 | 听 | 35,470 | 听 |
| Other long-term assets | 听 | 256 | 听 | 听 | 听 | 256 | 听 |
| Total assets | $ | 335,250 | 听 | 听 | $ | 483,834 | 听 |
| LIABILITIES AND STOCKHOLDERS鈥� EQUITY | |||||||
| Current liabilities: | 听 | 听 | 听 | ||||
| Accounts payable | $ | 3,329 | 听 | 听 | $ | 4,002 | 听 |
| Accrued expenses | 听 | 30,197 | 听 | 听 | 听 | 39,501 | 听 |
| Current portion of operating lease liability | 听 | 2,001 | 听 | 听 | 听 | 1,925 | 听 |
| Total current liabilities | 听 | 35,527 | 听 | 听 | 听 | 45,428 | 听 |
| Liability related to sale of future royalties | 听 | 331,361 | 听 | 听 | 听 | 353,426 | 听 |
| Operating lease liability, net of current portion | 听 | 13,095 | 听 | 听 | 听 | 14,112 | 听 |
| Stockholders鈥� equity: | 听 | 听 | 听 | ||||
| Preferred stock, | 听 | 鈥� | 听 | 听 | 听 | 鈥� | 听 |
| Common stock, | 听 | 28 | 听 | 听 | 听 | 30 | 听 |
| Additional paid in capital | 听 | 792,531 | 听 | 听 | 听 | 829,860 | 听 |
| Accumulated other comprehensive (loss) gain | 听 | (6 | ) | 听 | 听 | 305 | 听 |
| Accumulated deficit | 听 | (837,286 | ) | 听 | 听 | (759,327 | ) |
| Total stockholders鈥� (deficit) equity | 听 | (44,733 | ) | 听 | 听 | 70,868 | 听 |
| Total liabilities and stockholders鈥� equity | $ | 335,250 | 听 | 听 | $ | 483,834 | 听 |
| 听 | |||||||||||||||
| AnaptysBio, Inc. Consolidated Statements of Operations and Comprehensive Loss (in thousands, except per share data) (unaudited) | |||||||||||||||
| 听 | |||||||||||||||
| 听 | Three Months Ended June 30, | 听 | Six Months Ended June 30, | ||||||||||||
| 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 | 听 | 听 | 2025 | 听 | 听 | 听 | 2024 | 听 |
| Collaboration revenue | $ | 22,263 | 听 | 听 | $ | 10,971 | 听 | 听 | $ | 50,034 | 听 | 听 | $ | 18,150 | 听 |
| Operating expenses: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Research and development | 听 | 37,824 | 听 | 听 | 听 | 41,997 | 听 | 听 | 听 | 79,004 | 听 | 听 | 听 | 79,039 | 听 |
| General and administrative | 听 | 10,609 | 听 | 听 | 听 | 9,295 | 听 | 听 | 听 | 24,739 | 听 | 听 | 听 | 21,633 | 听 |
| Total operating expenses | 听 | 48,433 | 听 | 听 | 听 | 51,292 | 听 | 听 | 听 | 103,743 | 听 | 听 | 听 | 100,672 | 听 |
| Loss from operations | 听 | (26,170 | ) | 听 | 听 | (40,321 | ) | 听 | 听 | (53,709 | ) | 听 | 听 | (82,522 | ) |
| Other income (expense), net: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Interest income | 听 | 3,654 | 听 | 听 | 听 | 4,623 | 听 | 听 | 听 | 8,067 | 听 | 听 | 听 | 9,207 | 听 |
| Non-cash interest expense for the sale of future royalties | 听 | (19,606 | ) | 听 | 听 | (10,953 | ) | 听 | 听 | (37,667 | ) | 听 | 听 | (17,270 | ) |
| Other income (expense), net | 听 | 3,531 | 听 | 听 | 听 | 鈥� | 听 | 听 | 听 | 5,433 | 听 | 听 | 听 | (2 | ) |
| Total other expense, net | 听 | (12,421 | ) | 听 | 听 | (6,330 | ) | 听 | 听 | (24,167 | ) | 听 | 听 | (8,065 | ) |
| Loss before income taxes | 听 | (38,591 | ) | 听 | 听 | (46,651 | ) | 听 | 听 | (77,876 | ) | 听 | 听 | (90,587 | ) |
| Provision for income taxes | 听 | (39 | ) | 听 | 听 | (9 | ) | 听 | 听 | (83 | ) | 听 | 听 | (9 | ) |
| Net loss | 听 | (38,630 | ) | 听 | 听 | (46,660 | ) | 听 | 听 | (77,959 | ) | 听 | 听 | (90,596 | ) |
| Unrealized (loss) gain on available for sale securities | 听 | (167 | ) | 听 | 听 | 209 | 听 | 听 | 听 | (311 | ) | 听 | 听 | 382 | 听 |
| Comprehensive loss | $ | (38,797 | ) | 听 | $ | (46,451 | ) | 听 | $ | (78,270 | ) | 听 | $ | (90,214 | ) |
| Net loss per common share: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Basic and diluted | $ | (1.34 | ) | 听 | $ | (1.71 | ) | 听 | $ | (2.62 | ) | 听 | $ | (3.35 | ) |
| Weighted-average number of shares outstanding: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | ||||||||
| Basic and diluted | 听 | 28,810 | 听 | 听 | 听 | 27,356 | 听 | 听 | 听 | 29,722 | 听 | 听 | 听 | 27,079 | 听 |
FAQ
What were AnaptysBio's (ANAB) key financial results for Q2 2025?
What were the Phase 2b trial results for rosnilimab in rheumatoid arthritis?
When will AnaptysBio (ANAB) receive the milestone payment from GSK?
What is AnaptysBio's cash runway projection?
What are the next major catalysts for AnaptysBio (ANAB)?
